Scancell Advances Cancer Study with Expert Support
Company Announcements

Scancell Advances Cancer Study with Expert Support

Scancell Holdings (GB:SCLP) has released an update.

Scancell Holdings Plc, a developer of novel immunotherapies, has received positive feedback from a panel of melanoma experts on its Phase 2/3 SCOPE study plans for treating cancer. The study, which is currently recruiting patients, is expected to present clinical results in late 2024 and early 2025. This milestone follows a successful presentation at ASCO, where Scancell’s clinical data received significant attention.

For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskScancell Holdings Moves Forward with Cancer Therapies
TipRanks UK Auto-Generated NewsdeskScancell Holdings Announces Major Shareholding Changes
TipRanks UK Auto-Generated NewsdeskScancell Holdings Welcomes New CEO Amid Strategic Shift
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App